Laboratorio de Imunopatologia Keizo Asami (LIKA), Universidade Federal de Pernambuco (UFPE), Recife, PE, BR.
Nucleo de Ciencias da Vida (NCV), Centro Academico do Agreste (CAA), Universidade Federal de Pernambuco (UFPE), Caruaru, PE, BR.
Clinics (Sao Paulo). 2021 Jan 20;76:e2142. doi: 10.6061/clinics/2021/e2142. eCollection 2021.
This study aimed to assess miRNA-195 expression in the tumor tissues from a cohort of Brazilian female breast cancer patients undergoing neoadjuvant chemotherapy (NAC) and evaluate its correlation with various clinicopathological markers.
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to evaluate the miRNA-195 expression in tumor tissues from a cohort of female breast cancer patients undergoing NAC. This expression was then correlated with the occurrence of several distinct breast cancer molecular subtypes and other clinicopathological variables.
A total of 55 patients were included in this study, 28 (50.9%) of whom were treated using NAC. Tumor miRNA-195 expression was suppressed in breast cancer patients, regardless of their exposure to systemic treatments, histological grade, size, nodal status, and tumor-node-metastasis (TNM) staging. This was more pronounced in luminal and triple-negative patients, and patient's response to NAC was correlated with an increase in miRNA-195 expression.
miRNA-195 is downregulated in the tumor tissues of Brazilian breast cancer patients regardless of NAC exposure; this reinforces its role as a tumor suppressor and a potential biomarker for chemotherapy response.
本研究旨在评估接受新辅助化疗（NAC）的巴西女性乳腺癌患者肿瘤组织中 miRNA-195 的表达，并评估其与各种临床病理标志物的相关性。
采用定量逆转录聚合酶链反应（qRT-PCR）检测接受 NAC 的女性乳腺癌患者肿瘤组织中 miRNA-195 的表达，然后将其与不同乳腺癌分子亚型的发生以及其他临床病理变量相关联。
本研究共纳入 55 例患者，其中 28 例（50.9%）接受了 NAC 治疗。无论是否接受系统治疗、组织学分级、大小、淋巴结状态和肿瘤-淋巴结-转移（TNM）分期，乳腺癌患者的肿瘤 miRNA-195 表达均受到抑制。在 luminal 和三阴性患者中更为明显，且患者对 NAC 的反应与 miRNA-195 表达的增加相关。
无论是否接受 NAC，巴西乳腺癌患者的肿瘤组织中均下调 miRNA-195；这进一步证实了其作为肿瘤抑制因子和化疗反应潜在生物标志物的作用。
